Curis to Present at Upcoming Healthcare Conferences in September
Curis Inc. (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor, has announced its participation in two upcoming healthcare conferences in September 2024. James Dentzer, President and CEO, will represent Curis at these events:
1. H.C. Wainwright 26th Annual Global Investment Conference (Sept. 9-11): Company presentation on Sept. 11 at 1:00 pm ET.
2. 2024 Cantor Fitzgerald Global Healthcare Conference (Sept. 17-19): Fireside chat on Sept. 17 at 3:05 pm ET.
Webcasts for both presentations will be available on the Curis website in the 'Investors' section, providing investors with opportunities to gain insights into the company's progress and strategy.
Curis Inc. (NASDAQ: CRIS), un'azienda biotecnologica che sta sviluppando emavusertib (CA-4948), un inibitore orale di IRAK4, ha annunciato la sua partecipazione a due prossimi conferenze sanitarie nel settembre 2024. James Dentzer, Presidente e CEO, rappresenterà Curis a questi eventi:
1. H.C. Wainwright 26ª Conferenza Globale Annuale sugli Investimenti (9-11 settembre): Presentazione dell'azienda il 11 settembre alle 13:00 ET.
2. Conferenza Globale Sanitaria 2024 di Cantor Fitzgerald (17-19 settembre): Chat informale il 17 settembre alle 15:05 ET.
I webcast per entrambe le presentazioni saranno disponibili sul sito web di Curis nella sezione 'Investitori', offrendo agli investitori opportunità per ottenere informazioni sui progressi e sulla strategia dell'azienda.
Curis Inc. (NASDAQ: CRIS), una compañía biotecnológica que está desarrollando emavusertib (CA-4948), un inhibidor oral de IRAK4, ha anunciado su participación en dos próximas conferencias de salud en septiembre de 2024. James Dentzer, Presidente y CEO, representará a Curis en estos eventos:
1. 26ª Conferencia Anual Global de Inversiones de H.C. Wainwright (9-11 de septiembre): Presentación de la empresa el 11 de septiembre a la 1:00 p.m. ET.
2. Conferencia Global de Salud 2024 de Cantor Fitzgerald (17-19 de septiembre): Charla junto a la chimenea el 17 de septiembre a las 3:05 p.m. ET.
Las transmisiones web para ambas presentaciones estarán disponibles en el sitio web de Curis en la sección 'Inversores', brindando a los inversores oportunidades para obtener información sobre el progreso y la estrategia de la empresa.
Curis Inc. (NASDAQ: CRIS), 에마부세르팁(CA-4948)이라는 경구용 IRAK4 억제제를 개발하는 생명공학 회사는 2024년 9월에 열릴 두 개의 보건 회의에 참가할 것이라고 발표했습니다. 제임스 덴처 대표이사 겸 CEO가 이 행사에 Curis를 대표하여 참석합니다:
1. H.C. Wainwright 제26회 연례 글로벌 투자 회의 (9월 9-11일): 9월 11일 오후 1시(ET)에 회사 프레젠테이션이 진행됩니다.
2. 2024 Cantor Fitzgerald 글로벌 보건 회의 (9월 17-19일): 9월 17일 오후 3시 5분(ET)에 파이어사이드 채팅이 있습니다.
두 발표에 대한 웹캐스트는 Curis 웹사이트의 '투자자' 섹션에서 제공되어, 투자자들이 회사의 진행 상황과 전략에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
Curis Inc. (NASDAQ: CRIS), une entreprise biopharmaceutique développant l'emavusertib (CA-4948), un inhibiteur oral de l'IRAK4, a annoncé sa participation à deux conférences de santé à venir en septembre 2024. James Dentzer, Président et PDG, représentera Curis lors de ces événements :
1. 26e Conférence Annuelle Mondiale sur l'Investissement de H.C. Wainwright (9-11 septembre) : Présentation de l'entreprise le 11 septembre à 13 h ET.
2. Conférence Mondiale sur la Santé 2024 de Cantor Fitzgerald (17-19 septembre) : Discussion informelle le 17 septembre à 15 h 05 ET.
Les webinaires pour les deux présentations seront disponibles sur le site de Curis dans la section 'Investisseurs', offrant aux investisseurs des opportunités d'obtenir des informations sur les progrès et la stratégie de l'entreprise.
Curis Inc. (NASDAQ: CRIS), ein Biotechnologieunternehmen, das emavusertib (CA-4948), einen oralen IRAK4-Inhibitor, entwickelt, hat seine Teilnahme an zwei bevorstehenden Gesundheitskonferenzen im September 2024 bekannt gegeben. James Dentzer, Präsident und CEO, wird Curis bei diesen Veranstaltungen vertreten:
1. 26. Jahreskonferenz für globale Investitionen von H.C. Wainwright (9.-11. September): Unternehmenspräsentation am 11. September um 13:00 Uhr ET.
2. 2024 Cantor Fitzgerald Globale Gesundheitskonferenz (17.-19. September): Gespräch am Kamin am 17. September um 15:05 Uhr ET.
Webcasts für beide Präsentationen werden auf der Curis-Website im Bereich 'Investoren' verfügbar sein, um den Investoren die Möglichkeit zu bieten, Einblicke in den Fortschritt und die Strategie des Unternehmens zu gewinnen.
- None.
- None.
The H.C. Wainwright 26th Annual Global Investment Conference being held September 9 – 11, 2024. Presentation details are as follows:
- Format: Company Presentation
- Date: Wednesday, September 11, 2024
- Time: 1:00 pm ET
- H.C. Wainwright webcast
The 2024 Cantor Fitzgerald Global Healthcare Conference being held September 17 – 19, 2024. Presentation details are as follows:
- Format: Fireside Chat
- Date: Tuesday, September 17, 2024
- Time: 3:05 pm ET
- Cantor webcast
Webcasts will be also available on the Curis website at www.curis.com in the 'Investors' section.
About Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study (CA-4948-102) in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS) with either a FLT3 mutation or a splicing factor mutation (U2AF1 or SF3B2), and as a frontline combination therapy with azacitidine and venetoclax in patents with AML (CA-4948-104). Emavusertib has received Orphan Drug Designation from the
View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-present-at-upcoming-healthcare-conferences-in-september-302237422.html
SOURCE Curis, Inc.
FAQ
What conferences will Curis (CRIS) attend in September 2024?
When is Curis (CRIS) presenting at the H.C. Wainwright conference?
What type of presentation will Curis (CRIS) give at the Cantor Fitzgerald conference?
Where can investors access the webcasts of Curis (CRIS) presentations?
What is the main product Curis (CRIS) is developing?
